D Ross Camidge

12PUBLICATIONS
141CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 03, 2026
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

|Jan 17, 2025
Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials.

David E Gerber, Claire R Wynters, Tanushree Prasad

|Dec 09, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer.

Mitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell

|Sep 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.

Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul

|Jul 24, 2024
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).

Luke R G Pike, Emily Miao, Lillian A Boe

|Jun 06, 2024
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.

D Ross Camidge, Jair Bar, Hidehito Horinouchi

Pageof 2

Frequent Collaborators

3 joint publications

Alexander Drilon

3 joint publications

David E Gerber

3 joint publications

Viola Zhu

2 joint publications

Ji-Youn Han